Clover Health Investments (NASDAQ:CLOV - Get Free Report) announced its earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03, Zacks reports. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%. The business had revenue of $336.96 million during the quarter, compared to analyst estimates of $347.41 million. Clover Health Investments updated its FY 2025 guidance to EPS.
Clover Health Investments Stock Performance
CLOV traded down $0.33 during trading on Monday, hitting $3.64. 7,510,574 shares of the stock were exchanged, compared to its average volume of 6,195,194. Clover Health Investments has a 1 year low of $0.61 and a 1 year high of $4.87. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -18.20 and a beta of 1.99. The firm has a 50 day simple moving average of $4.04 and a 200 day simple moving average of $3.60.
Analyst Ratings Changes
CLOV has been the subject of a number of recent analyst reports. Craig Hallum began coverage on Clover Health Investments in a report on Tuesday, December 17th. They set a "buy" rating and a $6.00 price objective for the company. Canaccord Genuity Group lifted their price objective on shares of Clover Health Investments from $4.20 to $4.50 and gave the company a "buy" rating in a report on Monday.
Get Our Latest Research Report on Clover Health Investments
Clover Health Investments Company Profile
(
Get Free Report)
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
Read More
Before you consider Clover Health Investments, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clover Health Investments wasn't on the list.
While Clover Health Investments currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
